Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-08-09

Clinical Trial Update: A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) [Phase 2]

View source ↗

Summary

Phase 2 study of mavacamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathy has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mavacamten (mavacamten)

Snippet

Sponsor: MyoKardia, Inc. | Conditions: Non-obstructive Hypertrophic Cardiomyopathy | Phase 2 | Status: COMPLETED | Results posted: 2022-08-09